Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rita Magriço.
Clinical Journal of The American Society of Nephrology | 2018
Rita Magriço; Miguel Bigotte Vieira; Catarina Dias; Lia Leitão; Joao Sergio Neves
BACKGROUND AND OBJECTIVES In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive systolic BP treatment (target <120 mm Hg) was associated with fewer cardiovascular events and higher incidence of kidney function decline compared with standard treatment (target <140 mm Hg). We evaluated the association between mean arterial pressure reduction, kidney function decline, and cardiovascular events in patients without CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We categorized patients in the intensive treatment group of the SPRINT according to mean arterial pressure reduction throughout follow-up: <20, 20 to <40, and ≥40 mm Hg. We defined the primary outcome as kidney function decline (≥30% reduction in eGFR to <60 ml/min per 1.73 m2 on two consecutive determinations at 3-month intervals), and we defined the secondary outcome as cardiovascular events. In a propensity score analysis, patients in each mean arterial pressure reduction category from the intensive treatment group were matched with patients from the standard treatment group to calculate the number needed to treat regarding cardiovascular events and the number needed to harm regarding kidney function decline. RESULTS In the intensive treatment group, 1138 (34%) patients attained mean arterial pressure reduction <20 mm Hg, 1857 (56%) attained 20 to <40 mm Hg, and 309 (9%) attained ≥40 mm Hg. Adjusted hazard ratios for kidney function decline were 2.10 (95% confidence interval, 1.22 to 3.59) for mean arterial pressure reduction between 20 and 40 mm Hg and 6.22 (95% confidence interval, 2.75 to 14.08) for mean arterial pressure reduction ≥40 mm Hg. In propensity score analysis, mean arterial pressure reduction <20 mm Hg presented a number needed to treat of 44 and a number needed to harm of 65, reduction between 20 and <40 mm Hg presented a number needed to treat of 42 and a number needed to harm of 35, and reduction ≥40 mm Hg presented a number needed to treat of 95 and a number needed to harm of 16. CONCLUSIONS In the intensive treatment group of SPRINT, larger declines in mean arterial pressure were associated with higher incidence of kidney function decline. Intensive treatment seemed to be less favorable when a larger reduction in mean arterial pressure was needed to attain the BP target.
Analytical Methods | 2015
J.E. Araújo; Tiago Santos; Susana Jorge; T. M. Pereira; Miguel Reboiro-Jato; R. Pavón; Rita Magriço; F. Teixeira-Costa; Aura Ramos; Hugo M. Santos
The aim of this study was to differentiate patients with glomerulonephritis and diabetic nephropathy using (i) peritoneal dialysate effluent, (ii) matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and (iii) bioinformatics tools. Profiles of peritoneal dialysate effluent were obtained using (a) sample preparation consisting of protein concentration through centrifugal concentrators and chemical-assisted protein depletion using DL-dithiothreitol, and (b) MALDI-TOF MS. A free open-source bioinformatics tool, Mass-UP, was used to classify such profiles using principal component analysis and hierarchical clustering. The methodology proposed here allows for classifying two different groups of patients with kidney failure, one with chronic glomerulonephritis and other with diabetic nephropathy.
Talanta | 2016
J.E. Araújo; Susana Jorge; Rita Magriço; Teixeira e Costa; Aura Ramos; Miguel Reboiro-Jato; Florentino Fdez-Riverola; Carlos Lodeiro; José Luis Capelo; Hugo M. Santos
Protein equalization with dithiothreitol, protein depletion with acetonitrile and the entire proteome were assessed in conjunction with matrix assisted laser desorption ionization time of flight mass spectrometry-based profiling for a fast and effective classification of patients with renal insufficiency. Two case groups were recruited as proof of concept, patients with chronic glomerulonephritis and diabetic nephropathy. Two key tools were used to develop this approach: protein concentration with centrifugal concentrator tubes with 10 KDa cut-off membranes and chemical assisted protein equalization with dithiothreitol or chemical assisted protein depletion with acetonitrile. In-house developed software was used to apply principal component analysis and hierarchical clustering to the profiles obtained. The results suggest that chemical assisted protein equalization with dithiothreitol is a methodology more robust than the other two ones, as the patients were well grouped by principal component analysis or by hierarchical clustering.
Nephrology Dialysis Transplantation | 2018
Miguel Bigotte Vieira; Rita Magriço; Catarina Viegas Dias; Lia Leitão; Joao Sergio Neves
BACKGROUND An inverse relationship between coffee consumption and mortality has been reported in the general population. However, the association between caffeine consumption and mortality in patients with chronic kidney disease (CKD) remains uncertain. METHODS We analysed 4863 non-institutionalized USA adults with CKD [defined by an estimated glomerular filtration rate (eGFR) of 15-60 mL/min/1.73 m2 and/or a urinary albumin:creatinine ratio >30 mg/g] in a nationwide study using the National Health and Nutrition Examination Survey (NHANES) 1999-2010. Caffeine consumption was evaluated by 24-h dietary recalls at baseline and all-cause, cardiovascular and cancer mortality were evaluated until 31 December 2011. We also performed an analysis of caffeine consumption according to its source (coffee, tea and soft drinks). Quartiles of caffeine consumption were <28.2 mg/day (Q1), 28.2-103.0 (Q2), 103.01-213.5 (Q3) and >213.5 (Q4). RESULTS During a median follow-up of 60 months, 1283 participants died. Comparing with Q1 of caffeine consumption, the adjusted hazard ratio for all-cause mortality was 0.74 [95% confidence interval (CI) 0.60-0.91] for Q2, 0.74 (95% CI 0.62-0.89) for Q3 and 0.78 (95% CI 0.62-0.98) for Q4 (P = 0.02 for trend across quartiles). There were no significant interactions between caffeine consumption quartiles and CKD stages or urinary albumin:creatinine ratio categories regarding all-cause mortality. CONCLUSIONS We detected an inverse association between caffeine consumption and all-cause mortality among participants with CKD.
Frontiers in Endocrinology | 2018
Joao Sergio Neves; Lia Leitão; Rita Magriço; M Bigotte Vieira; C Viegas Dias; Álvaro Oliveira; Davide Carvalho; B Claggett
Aim: An inverse relationship between coffee consumption and mortality has been reported in the general population. However, the effect of coffee consumption in diabetes remains unclear. We aimed to evaluate the association of caffeine consumption and caffeine source with mortality among patients with diabetes. Methods: We examined the association of caffeine consumption with mortality among 1974 women and 1974 men with diabetes, using the National Health and Nutrition Examination Survey (NHANES) 1999–2010. Caffeine consumption was assessed at baseline using 24 h dietary recalls. Cox proportional hazard models were fitted to estimate hazard ratios (HR) for all-cause, cardiovascular, and cancer-related mortality according to caffeine consumption and its source, adjusting for potential confounders. Results: A dose-dependent inverse association between caffeine and all-cause mortality was observed in women with diabetes. Adjusted HR for death among women who consumed caffeine, as compared with non-consumers, were: 0.57 (95% CI, 0.40–0.82) for <100 mg of caffeine/day, 0.50 (95% CI, 0.32–0.78) for 100 to <200 mg of caffeine/day, and 0.39 (95% CI, 0.23–0.64) for ≥200 mg of caffeine/day (p = 0.005 for trend). This association was not observed in men. There was a significant interaction between sex and caffeine consumption (p = 0.015). No significant association between total caffeine consumption and cardiovascular or cancer mortality was observed. Women who consumed more caffeine from coffee had reduced risk of all-cause mortality (p = 0.004 for trend). Conclusion: Our study showed a dose-dependent protective effect of caffeine consumption on mortality among women with diabetes.
The Lancet Diabetes & Endocrinology | 2018
Joao Sergio Neves; Lia Leitão; Rita Magriço; Catarina Viegas Dias; Miguel Bigotte Vieira
Nephrology Dialysis Transplantation | 2018
Rute Baeta Baptista; Joao Sergio Neves; Rita Magriço; Lia Leitão; Miguel Bigotte Vieira
Journal of the American College of Cardiology | 2018
Miguel Bigotte Vieira; Rita Magriço; Catarina Dias; Lia Leitão; Joao Sergio Neves
20th European Congress of Endocrinology | 2018
Joao Sergio Neves; Miguel Bigotte Vieira; Rita Magriço; Lia Leitão; Catarina Dias; Rute Baeta Baptista; Ana Oliveira; Davide Carvalho
20th European Congress of Endocrinology | 2018
Joao Sergio Neves; Catarina Dias; Lia Leitão; Miguel Bigotte Vieira; Rita Magriço; Ana Isabel Oliveira; Inês Falcão-Pires; André P. Lourenço; Davide Carvalho; Adelino F. Leite-Moreira